DrugPatentWatch Database Preview
Astellas Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for ASTELLAS, and when can generic versions of ASTELLAS drugs launch?
ASTELLAS has thirty-three approved drugs.
There are eleven US patents protecting ASTELLAS drugs.
There are two hundred and sixty-two patent family members on ASTELLAS drugs in thirty-eight countries and fifty-three supplementary protection certificates in sixteen countries.
Summary for Astellas
| International Patents: | 262 |
| US Patents: | 11 |
| Tradenames: | 18 |
| Ingredients: | 14 |
| NDAs: | 33 |
| Patent Litigation for Astellas: | See patent lawsuits for Astellas |
Drugs and US Patents for Astellas
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | ADENOCARD | adenosine | INJECTABLE;INJECTION | 019937-002 | Oct 30, 1989 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Astellas | ARISTOCORT A | triamcinolone acetonide | OINTMENT;TOPICAL | 088780-001 | Oct 1, 1984 | DISCN | No | No | Start Trial | Start Trial | |||||
| Astellas | ARISTOCORT A | triamcinolone acetonide | OINTMENT;TOPICAL | 080745-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| Astellas | PROGRAF | tacrolimus | INJECTABLE;INJECTION | 050709-001 | Apr 8, 1994 | AP | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Astellas | CRESEMBA | isavuconazonium sulfate | POWDER;INTRAVENOUS | 207501-001 | Mar 6, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Astellas | XTANDI | enzalutamide | CAPSULE;ORAL | 203415-001 | Aug 31, 2012 | RX | Yes | Yes | 8,183,274 | Start Trial | Start Trial | ||||
| Astellas | ARISTOCORT | triamcinolone | TABLET;ORAL | 011161-009 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Astellas
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 9,045,519 | Start Trial |
| Astellas | VESICARE | solifenacin succinate | TABLET;ORAL | 021518-002 | Nov 19, 2004 | 6,017,927*PED | Start Trial |
| Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,582,617 | Start Trial |
| Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-001 | May 18, 1995 | 5,070,877 | Start Trial |
| Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,655,637 | Start Trial |
| Astellas | ASTAGRAF XL | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 204096-002 | Jul 19, 2013 | 8,551,522 | Start Trial |
| Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-002 | Mar 16, 2005 | 5,376,634 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTELLAS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 40 mg | ➤ Subscribe | 2016-08-31 |
| ➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-18 |
| ➤ Subscribe | Injection | 0.08 mg/mL, 5 mL vial | ➤ Subscribe | 2012-04-10 |
| ➤ Subscribe | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg | ➤ Subscribe | 2013-11-15 |
| ➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2014-06-16 |
| ➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-16 |
| ➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2009-04-08 |
International Patents for Astellas Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 024634 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007092372 | Start Trial |
| Japan | 2011068653 | Start Trial |
| Russian Federation | 2449993 | Start Trial |
| European Patent Office | 2013187 | Start Trial |
| China | 1185230 | Start Trial |
| South Korea | 101494125 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Astellas Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1893196 | 491 | Finland | Start Trial | |
| 1893196 | SPC/GB13/079 | United Kingdom | Start Trial | PRODUCT NAME: ENZLUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/846 20130625 |
| 1893196 | C300632 | Netherlands | Start Trial | PRODUCT NAME: ENZALUTAMIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/846 20130621 |
| 1189916 | CA 2011 00005 | Denmark | Start Trial | PRODUCT NAME: REGADENOSON OG SALTE DERAF |
| 1280795 | 5/2016 | Austria | Start Trial | PRODUCT NAME: ISAVUCONAZOL ALS ISAVUCONAZONIUMSULFAT ODER ALS EIN ISAVUCONAZONIUMSALZ MIT EINEM ANDEREN PHARMAZEUTISCH ANNEHMBAREN ANION, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS; REGISTRATION NO/DATE: EU/1/15/1036 (MITTEILUNG) 20151015 |
| 1893196 | CR 2013 00065 | Denmark | Start Trial | PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625 |
| 0788511 | C00788511/01 | Switzerland | Start Trial | PRODUCT NAME: MICAFUNGIN; REGISTRATION NO/DATE: SWISSMEDIC 60724 11.07.2012 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
